These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12569291)

  • 1. Patterns of failure in patients with malignant melanoma treated with high-dose interferon-alpha2b in the adjuvant setting.
    Schachter J; Brenner B; Fenig E; Gutman R; Sulkes A; Gutman H
    Melanoma Res; 2003 Feb; 13(1):93-6. PubMed ID: 12569291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
    Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
    Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
    Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
    J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
    Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
    Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS; Kirkwood JM
    Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon.
    Ascierto PA; Daponte A; Parasole R; Perrone F; Caracò C; Melucci M; Palmieri G; Napolitano M; Mozzillo N; Castello G
    Cancer; 2000 Oct; 89(7):1490-4. PubMed ID: 11013362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.
    Garbe C; Radny P; Linse R; Dummer R; Gutzmer R; Ulrich J; Stadler R; Weichenthal M; Eigentler T; Ellwanger U; Hauschild A
    Ann Oncol; 2008 Jun; 19(6):1195-201. PubMed ID: 18281266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.
    Kleeberg UR; Suciu S; Bröcker EB; Ruiter DJ; Chartier C; Liénard D; Marsden J; Schadendorf D; Eggermont AM;
    Eur J Cancer; 2004 Feb; 40(3):390-402. PubMed ID: 14746858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients.
    Conill C; Jorcano S; Domingo-Domènech J; Marruecos J; Vilella R; Malvehy J; Puig S; Sánchez M; Gallego R; Castel T
    Melanoma Res; 2007 Oct; 17(5):304-9. PubMed ID: 17885585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
    Agarwala SS
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].
    Chiarion-Sileni V; Del Bianco P; Romanini A; Guida M; Paccagnella A; Dalla Palma M; Naglieri E; Ridolfi R; Silvestri B; Michiara M; De Salvo GL
    BMC Cancer; 2006 Feb; 6():44. PubMed ID: 16504154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
    Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
    J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta-analysis of three trials.
    Malczewski A; Marshall A; Payne MJ; Mao L; Bafaloukos D; Si L; Pectasides D; Fountzilas G; Guo J; Gogas H; Middleton MR
    Cancer Med; 2016 Jan; 5(1):17-23. PubMed ID: 26645567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).
    Agarwala SS; Lee SJ; Yip W; Rao UN; Tarhini AA; Cohen GI; Reintgen DS; Evans TL; Brell JM; Albertini MR; Atkins MB; Dakhil SR; Conry RM; Sosman JA; Flaherty LE; Sondak VK; Carson WE; Smylie MG; Pappo AS; Kefford RF; Kirkwood JM
    J Clin Oncol; 2017 Mar; 35(8):885-892. PubMed ID: 28135150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
    Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
    J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma -- a retrospective single centre study.
    Gyorki DE; Ainslie J; Joon ML; Henderson MA; Millward M; McArthur GA
    Melanoma Res; 2004 Jun; 14(3):223-30. PubMed ID: 15179193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
    Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
    Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.